Grail, Inc. (NASDAQ:GRAL) CFO Sells $426,937.04 in Stock

Grail, Inc. (NASDAQ:GRAL) CFO Aaron Freidin sold 30,452 shares of the stock in a transaction that occurred on Monday, November 18th. The shares were sold at an average price of $14.02, for a total transaction of $426,937.04. Following the sale, the chief financial officer now directly owns 268,277 shares of the company’s stock, valued at $3,761,243.54. The trade was a 10.19 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website.

Grail Price Performance

Shares of NASDAQ:GRAL traded up $0.79 during midday trading on Tuesday, reaching $14.79. The company’s stock had a trading volume of 416,469 shares, compared to its average volume of 1,090,092. Grail, Inc. has a twelve month low of $12.33 and a twelve month high of $23.36. The firm has a fifty day moving average price of $13.84.

Analyst Upgrades and Downgrades

A number of research firms recently commented on GRAL. Wolfe Research began coverage on shares of Grail in a research report on Friday. They set a “peer perform” rating for the company. Guggenheim assumed coverage on shares of Grail in a research note on Thursday, October 17th. They set a “neutral” rating on the stock.

Grail Company Profile

GRAIL, Inc, a biotechnology company, focuses on developing technologies for early cancer detection. The company develops Galleri, a screening test for asymptomatic individuals over 50 years of age; and DAC, a diagnostic aid for cancer tests to accelerate diagnostic resolution for patients for whom there is a clinical suspicion of cancer.